Astrasana Pharma AG has successfully completed the setup of its pharmaceutical production facility in Tagelswangen, Canton Zurich.
The facility is designed for the cultivation of medical cannabis under Swissmedic licence and meets the strictest pharmaceutical quality standards.
State-of-the-Art Infrastructure
The production facility includes:
- Climate-controlled cultivation rooms with full environmental control
- Pharmaceutical processing and packaging areas
- An integrated quality control laboratory
- Storage and logistics areas in accordance with GDP standards
Significance for the Swiss Market
With the commissioning of the Tagelswangen facility, Astrasana strengthens its position as one of the leading players in the Swiss medical cannabis market. Local production enables shorter supply chains and even tighter quality control.
Vertical Integration
The Tagelswangen production facility is a central component of Astrasana’s vertical integration strategy. From cultivation through processing to packaging, all production steps take place under one roof. This ensures complete traceability for every batch and minimises the risk of quality deviations.
The Swissmedic-compliant facility is designed to scale with growing demand. Modular cultivation rooms allow production capacity to be flexibly adjusted to market developments without requiring fundamental structural changes.
Location Advantage in Canton Zurich
The choice of Tagelswangen in Canton Zurich offers numerous advantages. Proximity to research institutions, universities, and Zurich Airport facilitates both scientific collaboration and logistics for national and international distribution. Furthermore, Astrasana benefits from the well-developed infrastructure and access to qualified professionals in the region.
The completion of the facility marks a significant step in Astrasana’s corporate development and lays the foundation for a sustainable, Swiss-based production of medical cannabis at the highest pharmaceutical level.
